Alder BioPharma closes $38m Series D financing
ALD518 is a monoclonal antibody to the pro-inflammatory cytokine IL-6, which is under Phase 2 development by Bristol-Myers Squibb for autoimmune diseases, and by Alder for cancer-related conditions.
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted priority medicines (PRIME) designation to AbelZeta Pharma’s C-CAR168.
Admet Predictor 6.0 now integrated with MedChem Designer offers graphical user interface improvements, expanded multidimensional graphics output and enhanced capabilities for exporting results. SLP Admet cheminformatics team leader